# Next‐generation Alzheimer's therapeutics: target assessment and enablement at the Indiana University School of Medicine–Purdue University TREAT‐AD Center

## TL;DR

This paper describes a new Alzheimer's research center that develops open-access tools to accelerate drug discovery for novel targets beyond amyloid and tau.

## Contribution

The paper introduces a milestone-driven, open science framework for developing Target Enabling Packages (TEPs) for Alzheimer's drug discovery.

## Key findings

- The TREAT-AD Center uses multi-omics and machine learning to identify high-priority targets beyond amyloid and tau.
- Cross-core workflows generate validated assays, biomarkers, and molecular probes for lead optimization.
- All data and tools are shared through the AD Knowledge Portal to support global Alzheimer's research.

## Abstract

The incidence of Alzheimer's disease (AD) continues to increase, despite decades of effort to develop disease‐modifying therapies. In response, the National Institute on Aging (NIA) established the TaRget Enablement to Accelerate Therapy Development for Alzheimer's Disease (TREAT‐AD) centers to address the gap between basic research and translational drug discovery. Situated within a robust AD research environment, the Indiana University School of Medicine (IUSM)–Purdue University TREAT‐AD Center is one of two National Institutes of Health (NIH)‐supported centers funded to accomplish this mission. With a focus on novel biological targets beyond amyloid and tau, our center has assembled the necessary components of a drug discovery engine: project and data management, bioinformatics and computational science, structural biology and biochemistry, assay development and pharmacology, and molecular design and synthesis of small molecules, antibodies, and oligonucleotides. Our objective is to deliver Target Enabling Packages (TEPs) within an open science framework, making data, methods, and research tools broadly accessible through the AD Knowledge Portal.

The Indiana University School of Medicine (IUSM)–Purdue TREAT‐AD Center develops Target Enabling Packages (TEPs) to advance novel targets for the treatment of Alzheimer's disease (AD).The center is overseen by an administrative core and operates through four technical cores – bioinformatics, structural biology, assay development, and medicinal chemistry – within a milestone‐driven and open science framework.Multi‐omics, systems biology, and machine learning (ML) approaches guide the nomination of high‐priority targets beyond amyloid and tau.Cross‐core workflows provide structural insights into novel biological targets, validated assays, biomarkers, and molecular probes that enable lead optimization.All data, methods, and tools are openly shared through the AD Knowledge Portal to accelerate global efforts in AD drug discovery.

The Indiana University School of Medicine (IUSM)–Purdue TREAT‐AD Center develops Target Enabling Packages (TEPs) to advance novel targets for the treatment of Alzheimer's disease (AD).

The center is overseen by an administrative core and operates through four technical cores – bioinformatics, structural biology, assay development, and medicinal chemistry – within a milestone‐driven and open science framework.

Multi‐omics, systems biology, and machine learning (ML) approaches guide the nomination of high‐priority targets beyond amyloid and tau.

Cross‐core workflows provide structural insights into novel biological targets, validated assays, biomarkers, and molecular probes that enable lead optimization.

All data, methods, and tools are openly shared through the AD Knowledge Portal to accelerate global efforts in AD drug discovery.